Edition:
United States

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

447.95INR
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
Rs447.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,104,673
52-wk High
Rs460.75
52-wk Low
Rs304.20

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare says Zydus gets FDA nod for muscle relaxant drug
Wednesday, 8 Mar 2017 12:11am EST 

Cadila Healthcare Ltd : Says Zydus Cadila receives final approval from the USFDA for tizanidine hydrochloride capsules .The muscle relaxant drug will be produced at the SEZ facility at Ahmedabad.  Full Article

Cadila Healthcare approves payment of interim dividend of 3.20 rupees per share
Tuesday, 7 Mar 2017 06:39am EST 

Cadila Healthcare Ltd :Says approved payment of interim dividend of INR 3.20 per share.  Full Article

Cadila Healthcare approves interim dividend at 3.20 rupees per share
Tuesday, 7 Mar 2017 06:24am EST 

Cadila Healthcare Ltd :Says approved the payment of interim dividend at INR 3.20/- per equity share.  Full Article

Cadila Healthcare says Zydus announces settlement with Supernus on Trokendi XR extended-release capsules
Tuesday, 7 Mar 2017 12:34am EST 

Cadila Healthcare Ltd : Says Zydus announces settlement with Supernus on Trokendi XR® (Topiramate) extended-release capsules . Says Supernus grants Zydus license to market Zydus generic version of Trokendi XR extnded release capsules from Jan 1 2023 . Says Zydus finalised agreement with Supernus Pharma to settle outstanding patent litigation related to Trokendi XR capsules .Other terms of settlement not disclosed.  Full Article

Supernus announces settlement with Zydus on Trokendi XR patent litigation
Monday, 6 Mar 2017 05:31pm EST 

Supernus Pharmaceuticals Inc : Supernus announces settlement with Zydus on Trokendi XR patent litigation . Supernus intends to continue its "vigorous" enforcement of its patent rights for Trokendi XR . Settlement agreement permits Zydus to begin selling generic version of Trokendi XR on Jan 1, 2023 .Supernus announces settlement with Zydus on Trokendi XR patent litigation.  Full Article

Cadila Healthcare says USFDA inspected formulations manufacturing facility at Baddi
Thursday, 2 Mar 2017 03:54am EST 

Cadila Healthcare Ltd : USFDA inspected our formulations manufacturing facility at Baddi from 20th February 2017 to 1st March 2017 . Says product is yet to be manufactured or marketed in the US . All three observations are related to pre-approval inspection (PAI) for a specific product filed. .Says there are no observations related to CGMP practices.  Full Article

Cadila Healthcare says Zydus' unit gets FDA nod for influenza drug
Monday, 27 Feb 2017 01:56am EST 

Cadila Healthcare Ltd : Says Zydus' Nesher Pharmaceuticals receives final approval from USFDA for oseltamivir phosphate capsules . Says drug to be produced at Nesher Pharmaceuticals USA manufacturing facility . Says oseltamivir phosphate is an anti-viral used in prevention, treatment of influenza virus infection . Says group also got final FDA nod to market Linezolid tablets . Says linezolid tabs USP is anti bacterial agent .Says Linezolid tablets will be produced at formulations manufacturing facility at pharma SEZ in Ahmedabad.  Full Article

Cadila Healthcare says Zydus gets USFDA approval for anti-fungal tablet
Friday, 17 Feb 2017 01:56am EST 

Cadila Healthcare Ltd :Says Zydus receives final approval from the USFDA for Fluconazole tablets USP and Clobetasol Propionate spray.  Full Article

Cadila Healthcare says FDA does not issue observation (483) to co's Moraiya unit
Thursday, 16 Feb 2017 04:13am EST 

Cadila Healthcare Ltd : The USFDA inspected company's moraiya facility from February 6, 2017 to February 15, 2017. .Says at the end of the inspection, no observation (483) is issued..  Full Article

Cadila Healthcare says Zydus gets final approval from USFDA for metroniazole tables
Sunday, 20 Nov 2016 11:23pm EST 

Cadila Healthcare Ltd :Zydus receives final approval from the USFDA for metroniazole tables.  Full Article

More From Around the Web

BRIEF-Cadila Healthcare approves payment of interim dividend of 3.20 rupees per share

* Says approved payment of interim dividend of INR 3.20 per share Source text: (http://bit.ly/2lzUWGj) Further company coverage: